UK's Sovereign AI fund now backs 12 companies, and wants to be their customer

The UK’s Sovereign AI programme has now invested in, or reached final legal agreements with, 12 UK AI companies, according to the third quarterly update from its chair, James Wise. Those companies have between them raised around £4B. The three investments named since the last update are the materials-AI firm CuspAI, the drug-discovery company Isomorphic Labs, and the chip startup OLIX.

The portfolio gives a clear read on where the government thinks the value lies. The bets span compute and infrastructure, the architectures behind frontier models, AI for health and life sciences, scientific discovery, and trust and security. In other words, the £500M fund is trying to place a hand across the whole stack rather than back a single theme. It is the picture a few months on from the first backings we covered in early August.

The more interesting signal is a change in how the programme plans to work. Alongside equity investments, it is preparing to launch procurement challenges: government departments will pose real problems, UK AI startups will compete to solve them, and Sovereign AI will act as the paying customer. Wise called procurement and advance market commitments “one of the most powerful levers any government has” to drive innovation, and he has a point. For many young companies a first serious customer, especially one as large as government, is worth more than another cheque. The team has also been on the road, running founder events in Newcastle, Glasgow, Cardiff, and Manchester, and now runs a jobs board across the portfolio.

It all sits inside the UK’s larger bet on building and owning more of its own AI, from the compute it runs on to the companies that use it, a bet that has drawn a large share of the country’s venture funding this year. The honest tension in a fund like this is whether public money picking winners crowds private capital in or nudges it around. On that question, becoming a customer and buying from startups is generally the healthier lever than the state trying to guess which company wins, so the procurement move is a promising direction to watch.